These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 28923539)

  • 21. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
    Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
    Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optical imaging and anticancer chemotherapy through carbon dot created hollow mesoporous silica nanoparticles.
    Kang MS; Singh RK; Kim TH; Kim JH; Patel KD; Kim HW
    Acta Biomater; 2017 Jun; 55():466-480. PubMed ID: 28373086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extracellular vesicles derived from dendritic cells loaded with VEGF-A siRNA and doxorubicin reduce glioma angiogenesis in vitro.
    Shamshiripour P; Rahnama M; Nikoobakht M; Rad VF; Moradi AR; Ahmadvand D
    J Control Release; 2024 May; 369():128-145. PubMed ID: 38522817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
    Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
    Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer cell membrane-cloaked mesoporous silica nanoparticles with a pH-sensitive gatekeeper for cancer treatment.
    Liu CM; Chen GB; Chen HH; Zhang JB; Li HZ; Sheng MX; Weng WB; Guo SM
    Colloids Surf B Biointerfaces; 2019 Mar; 175():477-486. PubMed ID: 30572156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts.
    Segerström L; Fuchs D; Bäckman U; Holmquist K; Christofferson R; Azarbayjani F
    Pediatr Res; 2006 Nov; 60(5):576-81. PubMed ID: 16988184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct cytosolic siRNA delivery by reconstituted high density lipoprotein for target-specific therapy of tumor angiogenesis.
    Ding Y; Wang Y; Zhou J; Gu X; Wang W; Liu C; Bao X; Wang C; Li Y; Zhang Q
    Biomaterials; 2014 Aug; 35(25):7214-27. PubMed ID: 24875759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Arming embolic beads with anti-VEGF antibodies and controlling their release using LbL technology.
    Sakr OS; Berndt S; Carpentier G; Cuendet M; Jordan O; Borchard G
    J Control Release; 2016 Feb; 224():199-207. PubMed ID: 26780173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and in vitro and in vivo evaluations of poly(ethylene glycol)-block-poly(4-vinylbenzylphosphonate) magnetic nanoparticles containing doxorubicin as a potential targeted drug delivery system.
    Hałupka-Bryl M; Asai K; Thangavel S; Bednarowicz M; Krzyminiewski R; Nagasaki Y
    Colloids Surf B Biointerfaces; 2014 Jun; 118():140-7. PubMed ID: 24769390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted multidrug delivery system to overcome chemoresistance in breast cancer.
    Tang Y; Soroush F; Tong Z; Kiani MF; Wang B
    Int J Nanomedicine; 2017; 12():671-681. PubMed ID: 28176940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-small cell lung cancer combination therapy: Hyaluronic acid modified, epidermal growth factor receptor targeted, pH sensitive lipid-polymer hybrid nanoparticles for the delivery of erlotinib plus bevacizumab.
    Pang J; Xing H; Sun Y; Feng S; Wang S
    Biomed Pharmacother; 2020 May; 125():109861. PubMed ID: 32070872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ZLM-7 exhibits anti-angiogenic effects via impaired endothelial cell function and blockade of VEGF/VEGFR-2 signaling.
    Su M; Huang J; Li J; Qin X; Tang X; Jin F; Chen S; Jiang C; Zou Z; Peng K; Nuruzzaman M; Zhang J; Luo J; Liu S; Luo Z
    Oncotarget; 2016 Apr; 7(14):19018-30. PubMed ID: 26967559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity.
    Wentink MQ; Hackeng TM; Tabruyn SP; Puijk WC; Schwamborn K; Altschuh D; Meloen RH; Schuurman T; Griffioen AW; Timmerman P
    Proc Natl Acad Sci U S A; 2016 Nov; 113(44):12532-12537. PubMed ID: 27791128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis, characterization, and immune efficacy of layered double hydroxide@SiO2 nanoparticles with shell-core structure as a delivery carrier for Newcastle disease virus DNA vaccine.
    Zhao K; Rong G; Guo C; Luo X; Kang H; Sun Y; Dai C; Wang X; Wang X; Jin Z; Cui S; Sun Q
    Int J Nanomedicine; 2015; 10():2895-911. PubMed ID: 25926734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
    Han L; Huang R; Liu S; Huang S; Jiang C
    Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic anti-tumor effects of bevacizumab and tumor targeted polymerized VEGF siRNA nanoparticles.
    Kim MG; Jo SD; Yhee JY; Lee BS; Lee SJ; Park SG; Kang SW; Kim SH; Jeong JH
    Biochem Biophys Res Commun; 2017 Jul; 489(1):35-41. PubMed ID: 28533089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer therapy and fluorescence imaging using the active release of doxorubicin from MSPs/Ni-LDH folate targeting nanoparticles.
    Li D; Zhang YT; Yu M; Guo J; Chaudhary D; Wang CC
    Biomaterials; 2013 Oct; 34(32):7913-22. PubMed ID: 23886730
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Doxorubicin loaded silica nanorattles actively seek tumors with improved anti-tumor effects.
    Gao F; Li L; Liu T; Hao N; Liu H; Tan L; Li H; Huang X; Peng B; Yan C; Yang L; Wu X; Chen D; Tang F
    Nanoscale; 2012 Jun; 4(11):3365-72. PubMed ID: 22538830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Core-matched nanoassemblies for targeted co-delivery of chemotherapy and photosensitizer to treat drug-resistant cancer.
    Jiang D; Xu M; Pei Y; Huang Y; Chen Y; Ma F; Lu H; Chen J
    Acta Biomater; 2019 Apr; 88():406-421. PubMed ID: 30763634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Weichang'an Formula Inhibits Tumor Growth in Combination with Bevacizumab in a Murine Model of Colon Cancer-Making up for the Deficiency of Bevacizumab by inhibiting VEGFR-1.
    Pan CF; Zhang X; Wang JW; Yang T; Zhong LLD; Shen KP
    Front Pharmacol; 2020; 11():512598. PubMed ID: 33746736
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.